Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Cipla is currently trading at Rs 315.70, up by 4.35 points or 1.40% from its previous closing of Rs 311.35 on the BSE.
The scrip opened at Rs 309.85 and has touched a high and low of Rs 318.00 and Rs 309.85 respectively. So far 202657 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 380.80 on 04-Jan-2011 and a 52 week low of Rs 273.60 on 06-Sep-2011.
Last one week high and low of the scrip stood at Rs 320.60 and Rs 284.00 respectively. The current market cap of the company is Rs 24998.96 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 33.43% and 29.62% respectively.
The other top giainers on BSE Healthcare (HC) space include Sun Pharmaceuticals up by 1.23%, Ranbaxy Laboratories up by 1.24%, Orchid Chemicals up by 1.15%, Fortis Healthcare up by 0..47% and Cadila Healthcare up by 0.27%.
India’s second largest drug maker by domestic sales, Cipla has reported a jump of 17.44% in its standalone net profit at Rs 308.97 crore for the second quarter ended September 30, 2011 on increased sales and cost savings. The company had posted a net profit of Rs 263.08 crore in the July-September quarter of the previous fiscal.
Total income of the company also rose by 9.16% to Rs 1802.33 crore during the reporting quarter from Rs 1651.03 crore in the year-ago period.
Exports to Africa were up 41% and the firm benefited from operational efficiencies in material consumption and product mix. Cipla’s sales in the domestic market grew on expected lines by 12%. Sales in Middle East were affected by changed market circumstances.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |